OS Therapies Inc
OST-HER2
prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for OST-HER2 in prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer.”